THROMBOPOIETIN RECEPTOR AGONIST ELTROMBOPAG FOR ADVANCED MDS OR AML AND SEVERE THROMBOCYTOPENIA: 12-WEEK, RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 ASPIRE STUDY

被引：0
|
作者：
Mittelman, M. [1 ]
Platzbecker, U. [2 ]
Afanasyev, B. [3 ]
Grosicki, S. [4 ]
Wong, R. S. [5 ,6 ]
Anagnostopoulos, A. [7 ]
Brenner, B. [8 ]
Denzlinger, C. [9 ]
Rossi, G. [10 ]
Nagler, A. [11 ]
Garcia Delgado, R. [12 ]
Stone, N. [13 ]
Zhu, Z. [13 ]
Kalambakas, S. [13 ]
Selleslag, D. [14 ]
机构：
[1] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, Tel Aviv, Israel
[2] Univ Klinikum Carl Gustav Carus, Dresden, Germany
[3] Pavlov State Med Univ, St Petersburg, Russia
[4] Silesian Med Univ, Katowice, Poland
[5] Chinese Univ Hong Kong, Sir YK Pao Ctr Canc, Shatin, Hong Kong, Peoples R China
[6] Chinese Univ Hong Kong, Dept Med & Therapeut, Shatin, Hong Kong, Peoples R China
[7] G Papanikolaou Gen Hosp, Thessaloniki, Greece
[8] Rambam Med Ctr, Haifa, Israel
[9] Marienhosp Stuttgart, Stuttgart, Germany
[10] Azienda Osped Spedali Civili, Brescia, Italy
[11] Chaim Sheba Med Ctr, Ramat Gan, Israel
[12] Hosp Virgen de la Victoria, Malaga, Spain
[13] Novartis Pharmaceut, E Hanover, NJ USA
[14] AZ St Jan Brugge AV, Brugge, Belgium
来源：
HAEMATOLOGICA | 2016年 / 101卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
S130
引用
收藏
页码：15 / 16
页数：2
相关论文
共 50 条
  • [41] Empagliflozin Monotherapy in Japanese Patients with Type 2 Diabetes Mellitus: a Randomized, 12-Week, Double-Blind, Placebo-Controlled, Phase II Trial
    Kadowaki, Takashi
    Haneda, Masakazu
    Inagaki, Nobuya
    Terauchi, Yasuo
    Taniguchi, Atsushi
    Koiwai, Kazuki
    Rattunde, Henning
    Woerle, Hans J.
    Broedl, Uli C.
    ADVANCES IN THERAPY, 2014, 31 (06) : 621 - 638
  • [42] Empagliflozin Monotherapy in Japanese Patients with Type 2 Diabetes Mellitus: a Randomized, 12-Week, Double-Blind, Placebo-Controlled, Phase II Trial
    Takashi Kadowaki
    Masakazu Haneda
    Nobuya Inagaki
    Yasuo Terauchi
    Atsushi Taniguchi
    Kazuki Koiwai
    Henning Rattunde
    Hans J. Woerle
    Uli C. Broedl
    Advances in Therapy, 2014, 31 : 621 - 638
  • [43] Efficacy and Safety of GPR119 Agonist DS-8500a in Japanese Patients with Type 2 Diabetes: a Randomized, Double-Blind, Placebo-Controlled, 12-Week Study
    Yamada, Yuichiro
    Terauchi, Yasuo
    Watada, Hirotaka
    Nakatsuka, Yasuhiko
    Shiosakai, Kazuhito
    Washio, Takuo
    Taguchi, Takashi
    ADVANCES IN THERAPY, 2018, 35 (03) : 367 - 381
  • [44] Efficacy and Safety of GPR119 Agonist DS-8500a in Japanese Patients with Type 2 Diabetes: a Randomized, Double-Blind, Placebo-Controlled, 12-Week Study
    Yuichiro Yamada
    Yasuo Terauchi
    Hirotaka Watada
    Yasuhiko Nakatsuka
    Kazuhito Shiosakai
    Takuo Washio
    Takashi Taguchi
    Advances in Therapy, 2018, 35 : 367 - 381
  • [45] MET409, an optimized farnesoid X receptor agonist, decreased liver fat and improved liver enzymes in patients with non-alcoholic steatohepatitis: a 12-week, randomized, placebo-controlled study
    Lawitz, Eric
    Bashir, Mustafa
    Shim-Lopez, Jennifer
    Lee, Jonathan
    Song, Ken
    Chen, Hubert
    Harrison, Stephen
    JOURNAL OF HEPATOLOGY, 2020, 73 : S132 - S132
  • [46] A 12-Week, Randomized, Placebo-Controlled Study Assessing the Efficacy and Safety of Three Dose-Escalation Algorithms of Tirzepatide, a Novel Dual GIP and GLP-1 Receptor Agonist, in Patients with Type 2 Diabetes
    Frias, Juan P.
    Nauck, Michael A.
    Van, Joanna
    Benson, Charles
    Bray, Ross
    Milicevic, Zvonko
    Haupt, Axel
    Robins, Deborah A.
    DIABETES, 2019, 68
  • [47] Diabetic gastroparesis: Effect of mitemcinal by subgroup analysis in a 12-week, randomized, multi-center, double-blind, placebo-controlled, phase 2b study
    McCallum, Richard W.
    Goldstein, Barry J.
    GASTROENTEROLOGY, 2006, 130 (04) : A598 - A598
  • [48] Olanzapine for the treatment of borderline personality disorder: A flexible-dose 12-week randomized double-blind placebo-controlled study
    Schulz, S. C.
    Zanarini, M. C.
    Detke, H. C.
    Trzaskoma, Q.
    Lin, D.
    DeBerdt, W.
    Corya, S.
    EUROPEAN PSYCHIATRY, 2007, 22 : S172 - S172
  • [49] Vortioxetine for Major Depressive Disorder in Adolescents: 12-Week Randomized, Placebo-Controlled, Fluoxetine-Referenced, Fixed-Dose Study
    Findling, Robert L.
    DelBello, Melissa P.
    Zuddas, Alessandro
    Emslie, Graham J.
    Ettrup, Anders
    Petersen, Maria L.
    Schmidt, Simon N.
    Rosen, Monika
    JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2022, 61 (09): : 1106 - +
  • [50] Olanzapine for the treatment of borderline personality disorder: A flexible-dose 12-week randomized double-blind placebo-controlled study
    Schulz, S. C.
    Zanarini, M.
    Detke, H.
    Trzaskoma, Q.
    Lin, D.
    DeBerdt, W.
    Corya, S.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2006, 9 : S191 - S191
12345